Diagnosis and management of dementia by Laban, P
Dementia is an acquired syndrome of memory decline with at least 
one other cognitive deficit in language, visuospatial, or executive 
function that alters personality, reduces intellect and interferes 
with functioning in an otherwise alert person. Multiple disease 
processes can result in a dementia syndrome (Table I). Alzheimer’s 
disease (AD) and vascular dementia (VaD) are the two most 
common.1 However, the incidence of HIV-associated dementia 
(HAD) has grown to as high as 31% in patients with HIV disease 
(Fig. 1).2 Less than 2% of cases of dementia are fully reversible.1 
Age is the strongest risk factor for dementia. Prevalence rises from 
1% in 60-year-olds to 50% in those over 95 years.3 Risk factors for 
AD include a first-degree relative with AD and the apolipoprotein 
E-epsilon4 genotype.4 An increased risk of both AD and VaD is 
found with cardiovascular risk factors like hypertension.5
Senile and pre-senile dementia were terms previously used to 
classify dementia based on age of onset. AD, now dementia of the 
Alzheimer’s type (DAT) was then a diagnosis by exclusion, being 
differentiated from the stepwise deterioration of multi-infarct 
dementia, by its gradually progressive course and insidious onset 
(Fig. 2). Despite the comprehensive evidence base that exists for 
the diagnosis and management of dementia, memory lapses in the 
elderly are still erroneously brushed off at primary care level as ‘just 
senility’.  
Common s ymptoms of dementia
Apathy, a loss of initiation and motivation resulting in social 
withdrawal and emotional indifference occurs early in VaD and 
later in 70% of patients with AD.5 Short-term, and later long-term, 
memory loss is an early feature of AD whereas executive dysfunction 
occurs early in VaD. Intellectual decline results from cognitive 
deficits. Behavioural and psychological symptoms in dementia 
(BPSD) like wandering, aggression, disruptive vocalisation, 
hallucinations and delusions are problematic to caregivers 
(Fig. 3). ‘Sundowning’ refers to the exacerbation of restlessness and 
agitation that occurs in the evening.
Diagnostic issues
Memory lapses with age, so differentiating between benign and 
pathological change is important. Age-related cognitive decline 
refers to any one cognitive deficit that is noticed by an objective, 
reliable source that causes the MMSE score to drop one standard 
deviation below the normal for that age.5 With mild cognitive 
impairment (MCI), which occurs in 12% of over 70s, there is 
objective memory impairment despite normal cognition and basic 
activities of daily living (BADL). The amnestic subtype of MCI has 
a 60% likelihood of progressing to AD.5 
Clinical distinction between AD and VaD is also challenging. 
Autopsies show 90% of AD patients have cerebrovascular pathology 
and 33% of VaD patients show AD brain changes.6 The incidence of 
mixed dementia is 20% of 6.8 million dementia patients in the USA.5 
Other causes of memory impairment like delirium, an altered state 
of consciousness due to medical conditions and depression, which 
presents with a pseudodementia that resolves with antidepressants, 
must be considered.
Diagnosis and management of dementia
Dementia will impose an increased social and economic burden 
 in the future.5
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Table I. Causes of dementia*
Neurodegenerative causes Potentially ‘reversible’ causes
Alzheimer’s disease  HIV-associated dementia  
Vascular dementia  Infections: meningitis, encephalitis 
Frontotemporal dementia Head injury    
Parkinson’s disease  Normal pressure hydrocephalus  
Lewy body dementia  Metabolic disorders: hypoglycaemia  
Huntington’s disease  Nutritional deficiencies: vitamin B12, folate 
Creutzfeld-Jakob disease Chronic alcoholism
















Fig. 1. Prevalence of types of dementia (AD = Alzheimer’s disease;  
VaD = vascular dementia; HAD = HIV-associated dementia;  
DLB = dementia with Lewy bodies; FTD = frontotemporal dementia 
(Modified from Lyketsos, et al.19).
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Alzheimer’s disease (Table II)
AD is the most common form of late-onset 
dementia. Memory difficulty is associated 
with disorientation or language dysfunction. 
Staging of the disease, which is based on ADL 
functioning, should be a priority during 
clinical assessment (Table III). Early deficits 
in word-finding difficulty are compensated 
for by the use of synonyms or definitions, so 
normal living is possible.12 Forgetting names, 
appointments and whether something has 
been done, losing things, difficulty with 
driving, cooking, household chores and 
personal finances are harder to conceal.12 
Uncharacteristic behaviour, paranoia and 
confusion in unfamiliar places prompt 
presentation to medical professionals.
By the moderate stage, BADLs like bathing, 
dressing, grooming, feeding and using the 
toilet, require supervision. Disorientation in 
familiar surroundings, loss of interest in the 
outside world, delusions, hallucinations and 
aggression follow. 
The severe stage is a total deterioration 
in BADL and complete dependence 
on others. Even close family members 
are not recognised, causing caregiver 
distress.  Medical complications including 
dehydration, malnutrition, aspiration, 
pressure sores, seizures and injuries from 
falls are common.5
Vascular dementia (Table IV) 
VaD, which is associated with a higher 
mortality than AD, can be cortical or 
subcortical. Disease may be focal, secondary 
to a thrombosis or embolus, or diffuse from 
hypertension.7 Multiple cortical infarcts can 
affect neural nets, a single strategic infarct 
like an anterior cerebral artery infarct can 
cause specific deficits and small-vessel 
disease can produce Binswanger’s disease 
and lacunar state.7,8 Onset is usually abrupt 
and a fluctuating or stepwise progression 
occurs, except in subcortical ischaemic 
vascular dementia where there may be a 
slow, progressive decline.7 
VaD patients have patchy deficits with better 
free recall when compared with AD.3 Apathy 
early in the disease, verbal fluency deficits 
and perseveration are more suggestive 
of VaD due to frontal lobe involvement. 
Strategic infarcts in the Wernicke or Broca 
areas cause dysarthrias, dysphasias and 
aphasias. Clinically, besides changes in 
personality, there may be unsteady gait, 
hyperreflexia, an extensor plantar response, 
hemiparesis, hemisensory deficits, visual 
field defects, diplopia and pseudobulbar 
syndrome. Executive function deficits in 
organising thoughts and initiating tasks are 
common.3,7,8 
HIV-associated dementia  
The HI-virus is neurotropic, but since 
HAART, HIV-associated dementia, which 
is predominantly subcortical, occurs 
mainly in the advanced stages or in severe 
immunosuppression. Forgetfulness, slowing 
of responses and difficulties in multitasking 
occur early while other cortical function 
is relatively preserved (Table V).9 Without 
significant immunosuppression, non-HIV-
related causes for memory loss like vitamin 
B12 deficiency, metabolic conditions and 
adverse drug interactions must first be 
excluded. 9
Other dementias
Dementia with Lewy bodies (DLB) presents 
with parkinsonism, delusions, visual 
hallucinations and fluctuating alertness. 
Cognitively, deficits in attention, visuospatial 
reasoning and frontal-subcortical function 
are observed.10 Comparatively, memory is 
Table II. DSM-IV-TR criteria for dementia, Alzheimer’s type*
•   A. Multiple cognitive deficits including both:
     - memory impairment, and 
      - at least one of the following: aphasia, apraxia, agnosia, disturbance in executive 
functioning
•   B.  Significant functional impairment
•   C. Course: gradual onset, continuing decline
•   D. Absence of neurological, medical or psychiatric condition
•   E. Absence of delirium
*Modified from American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed.15
Table IV. DSM-IV-TR criteria for vascular dementia*
•    A. Multiple cognitive deficits including both:
       - memory impairment, and  
       -  at least one of the following: aphasia, apraxia, agnosia, disturbance in executive 
functioning
•    B.  Focal neurological signs and symptoms or radiological evidence of cerebrovascular 
disease assessed to be aetiologically related to the dementia
•    C.  Cognitive deficits cause significant impairment in functioning and a decline from 
previous level of functioning
•   D. Absence of delirium
*Modified from American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed.15
Table III. Staging of Alzheimer’s disease
     MMSE     
Stage    Characteristic   score  Placement
Mild    Noticeable cognitive defects; 20 - 26  Can live at home  
    independent living    alone
Moderate   Cognitive decline; dependence 10 - 19  Needs supervision  
    on caregivers; physical changes
Severe    Total dependence on caregivers < 10  Placement in frail  
    for basic activities of daily living;   care advisable or 24- 
    personality deterioration; loss of   hour nursing   
    control of body functions    required at home
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significantly worse in AD, while visuospatial 
function and executive abilities are worse in 
DLB.11 
Forty per cent of patients with idiopathic 
Parkinson’s disease have frontal-subcortical 
dementia, in which frontal executive 
functions and memory retrieval are the 
most impaired.12 Lewy bodies are found in 
the cortex at autopsy, suggesting that this 
represents a variant of DLB.
In frontotemporal dementia early be-
havioural changes precede the loss of 
memory. Onset is insidious and progressive, 
typically between 45 and 65 years. 
Disinhibition, poor impulse control, poor 
grooming and hygiene can occur.13
Huntington’s disease begins generally in 
middle life. Neuropsychiatric symptoms of 
depression, apathy, aggression, disinhibition 
and social disintegration may predate the 
chorea.5 
Creutzfeld-Jakob disease is rapidly 
progressive in middle life, although a young-
onset form exists. Prodromal psychiatric 
symptoms are followed by myoclonus and 
possibly seizures, extrapyramidal signs, 
cerebellar ataxia, and cortical blindness.9 
Young-onset dementia (YOD) occurs in 
about 67 - 81/100 000 in the 45 - 65-year old 
age group.12 Although AD, VaD and HAD 
occur, the differential diagnosis includes 
mainly genetic and metabolic disorders. 
Pyramidal, extrapyramidal, cerebellar or 
peripheral nerve involvement provides key 
diagnostic clues. Drugs and toxic exposures 
must be considered. In 10% of cases the 
condition is due to chronic alcohol abuse.5
Clinical assessment
The clinical diagnostic process should 
not focus on any single set of criteria. 
Clinical history, physical and neurological 
examinations and neuropsychological 
tests including the Mini Mental State 
Examination (MMSE) (Table VI), the 
modified HIV dementia scale in HIV 
disease (Table VII), the Hachinski dementia 
scale in vascular risk (Table VIII) and the 
geriatric depression rating scale (Table IX) 
in the presence of a depressive process, 
should be done. Investigations including full 
blood count (FBC), thyroid function (TFT), 
urea and electrolytes (U&E), erythrocyte 
sedimentation rate (ESR), C-reactive protein 
(CRP), syphilis serology, calcium serum 
level, fasting glucose, lipid profile, vitamin 
B12, folate, HIV serology and brain imaging, 
are considered appropriate management.14 
Management
Principles of management are: 
•    establish the diagnosis of dementia; 
•    stage the severity; 
•    assess available support. 
Causally linking risk factors is important 
for patients with VaD. Early diagnosis is 
essential. Identification of patients with 
potentially reversible conditions, or with 
at-risk conditions like MCI, is crucial to a 
better prognosis. In progressive disorders 
early decision-making, the planning of 
appropriate treatment, early psychosocial 
intervention, and caregiver training will 
improve quality of life outcomes. Early 
initiation of drug treatment in AD stabilises 
the level of functioning present at the time 
of diagnosis and promotes quality of life for 
patient, caregivers and families.5 An MMSE 
every 6 months in MCI patients can help 
document changes over time. 
Pharmacological options (Table X)
Reversible acetylcholinesterase inhibitors 
(AChEI) like donepezil, galantamine, and 
rivastigmine, and the N-methyl-D-aspartate 
(NMDA) receptor modulator memantine, 
Table VI. The Mini Mental State Examination*
•    Orientation:  First, ask the patient the date, day, month, year, and season. The maxi-
mum score is 5.
      Second, ask the patient their current location, i.e. clinic, floor, town, province, and 
country. The maximum score is 5.
•    Registration: Name 3 objects (e.g. apple, penny, table), and ask the patient to repeat 
them. The maximum score is 3.
•    Attention:  Ask the patient to spell the word ‘world’ backwards or to subtract 7 from 
100 serially backwards (stop after 5 answers). The maximum score is 5.
•    Recall: Ask the patient to remember the 3 objects from the registration portion of the 
test. The maximum score is 3.
•    Language 
 •    Ask the patient to identify a pencil and a watch. The maximum score is 2.
 •    Ask the patient to repeat the phrase ‘no ifs, ands, or buts’. The maximum 
score is 1.
 •    Ask the patient to follow a 3-step command. The maximum score is 3. 
 •    Ask the patient to read and obey the phrase ‘close your eyes’. The maximum 
score is 1. 
 •    Ask the patient to write a sentence. The maximum score is 1. 
 •    Ask the patient to copy a set of interlocking pentagons. The maximum score 
is 1.
•    Scoring: The maximum score possible is 30. Generally, any score less than 24 is con-
sidered abnormal, but the cut-off varies with the patient’s level of education. Because 
the results for this test can vary over time it is important to record the date and time 
of the assessment.
*Modified from Folstein, et al.16
Table V. Clinical features of HIV-associated dementia (HAD)*
Cluster of symptoms         Presentation
Neurological  •    Motor symptoms: weakness, altered fine motor skills 
(handwriting) 
   •   Unsteady gait 
   •   Tremor 
   •   Visuospatial memory and coordination difficulties
   •   Impaired verbal memory (word-finding)
   •   Impaired attention and concentration 
   •   Mental slowing
Psychiatric  •   Psychomotor retardation (slowed speech)
   •   Personality changes (aggression, suspicion)
   •   Social withdrawal 
   •   Apathy 
   •   Irritability 
   •   Depression
   •   Mania
   •   Psychotic symptoms (paranoia)
   •   Anxiety, obsessive or panic symptoms
*Modified from Davis, et al.9
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are two of the drug options available. Vitamin 
E has shown efficacy at a dose of 1 000 µg 
daily in some patients.5 AChEIs reduce 
neuropsychiatric symptoms. Apathy shows 
the most consistent response.8 Switching 
within the class is a good option where there 
is intolerance.5 The treatment goal of the 
early initiation with an AChEI is stability 
of symptoms. Improvements may be noted 
but no change is a positive outcome in AD. 
The decision to terminate treatment should 
be individualised, but a general guideline is 
when the MMSE falls below 10. Compliance 
is critical as functioning drops acutely on 
withdrawal of AChEIs. Memantine has 
efficacy in moderate to severe AD and, 
used together with donepezil, improves 
behavioural problems.5 Cost-effectiveness of 
pharmacological intervention in AD is well 
documented. Treatment results in lower total 
health care costs for patients and caregivers 
and delayed nursing home placement.5 Six-
monthly MMSE scoring is important when 
AChEIs are used to plot disease progression 
and adjust doses. 
The mainstay of therapy for patients with 
HAD is HAART.9 With mild cognitive 
deficits, memantine and low-dose selegiline 
have been used successfully.5 Modification 
of vascular risks can delay the onset of 
dementia.3 Identification of target high-
risk groups is therefore a priority. Lifestyle 
changes may involve diet, exercise, stress 
reduction, control of hyperlipidaemia 
and cessation of smoking. Anticoagulants 
should be considered for atrial fibrillation, 
antiplatelet agents after transient ischaemic 
attacks or non-haemorrhagic stroke and 
carotid endarterectomy for severe carotid 
stenosis.3,7,8 There is growing evidence 
of cholinergic involvement in VaD, and 
donepezil has shown efficacy above placebo.8 
Recommended doses for VaD mirror those 
for AD.
D ementia
Table VII. The modified HIV dementia scale*
Score (maximum)
  Memory – registration 
Give 4 words to recall (dog, hat, green, peach), 1 second to say each; then, ask 
the patient to repeat all 4.
 Psychomotor speed 
(6)  Ask patient to write alphabet in upper case letters horizontally, and record   
 time in seconds.
 Memory – recall 
(4)  Ask for 4 words from registration above; give 1 point for each correct word.   
 (For words not recalled, prompt with a cue.)
 Constructional 
(2)  Ask patient to copy 3-dimensional cube (below); record time in seconds.
(12) Total
*Source: Davis, et al.9
Table VIII. Hachinski ischaemic scale*
Clinical features     Score  Clinical feature        Score
Abrupt onset     2  Emotional incontinence         1
Stepwise deterioration    1  Hypertension          1
Fluctuating course     2  History of stroke           2
Nocturnal confusion    1  Associated atherosclerosis         1
Preservation of personality    1  Focal neurological symptoms       2
Depression     1  Focal neurological signs          2
Somatic complaints    1  Total          18
*Source: Hachinski V, et al.17
Fig. 2. The course of AD
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Fig. 2. The course of AD (Modified from Potocnik, et al.4).
Years relative t  t e iag sis of Alzhei er's disease
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Depression is a feature that commonly 
accompanies AD and escitalopram, a 
selective serotonin receptor inhibitor 
(SSRI), has been used effectively. Tricyclic 
antidepressants are of limited usefulness 
because of sedation and anticholinergic 
side-effects. BPSD are associated with a 
poor outcome: reduced ability to care for 
self and time to institutionalisation and 
a lower rate of survival with increased 
caregiver burden and economic costs.5 
Atypical antipsychotics are useful in 
managing BPSD. Low-dose olanzapine, 
5 - 10 mg daily, reduces psychosis and 
agitation with no significant increase in 
extrapyramidal side-effects. Risperidone, 
which is registered for BPSD, is effective 
at 0.5 - 1.5 mg/day. Quetiapine, 25 - 100 
mg daily, is a feasible alternative and 
may produce fewer extrapyramidal side-
effects. 
Non-pharmacological options
Environmental change, caregiver and 
family support are important. Homes 
should be modified early on to ensure 
safety.  Diaries and other forms of 
reminders assist in functioning optimally. 
Medicolegal issues should be a priority 
after diagnosis: discussion around driving, 
firearm possession, wills, living wills and 
decisions about placement should occur 
early with the patient, caregiver and 
family. Caregivers should be encouraged 
to attend caregiver support groups and to 
take advantage of respite care offered by 
community organisations, as it reduces 
caregiver burden.
The late stages of AD and most dementias 
are marked by complete functional 
dependence. Patients are non-ambulatory, 
unable to communicate needs and may 
be unable to feed themselves. End-of-life 
issues must be addressed with patients 
and family members before this stage 
is reached, as many people have strong 
feelings regarding use of intravenous 
hydration or nasogastric or percutaneous 
gastrostomy tubes for life support.5 
Conclusion
The prevalence of dementia is rising 
as health care improves and the aged 
population grows older and increases. 
Dementia will impose an increased social 
and economic burden in the future.5 The 
diagnosis of dementia is mainly clinical 
and must include cognitive assessment. 
Treatments that delay the progression or 
improve the symptoms of AD should be 
started early to improve the prognosis. 
The management of neuropsychiatric 
symptoms with atypical antipsychotics 
is also important for improving the 
quality of life for patients and caregivers. 
In patients with HIV disease, HAART 
is the best treatment option to reduce 
HAD. Clinicians must recognise cognitive 
decline early in their patient population, 
preferably at the level of MCI, and 
commence treatments that will delay or 
prevent the onset of dementia. 
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D ementia
In a nutshell 
•    Dementia is an acquired impairment in memory with one or more cognitive deficits that affect personality and intellect resulting in 
impairment in functioning.
•    Alzheimer’s disease (AD), vascular dementia (VaD) and HIV-associated dementia (HAD) are the three most common dementias.
•    Behavioural and psychological symptoms of dementia are associated with a poor outcome.
•    The MMSE can be used to stage AD.
•    Three acetylcholinesterase inhibitors and memantine are currently available to treat AD.
•    Treatment of risk factors like hypertension, diabetes, hyperlipidaemia and the cessation of smoking is important in the management 
of VaD.
•    The introduction of HAART has significantly reduced the incidence of HAD.
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